Side-by-side financials for EDIT and GILD. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | EDIT | GILD |
|---|---|---|
| Market cap | - | $155.93 B |
| US-listed rank | - | #98 |
| Revenue (latest FY) | $40.52M | $29.44B |
| Net income (latest FY) | -$160.06M | $8.51B |
| Net margin | -395.0% | 28.9% |
| P/E (trailing FY) | - | 18.3 |
| SEC filings | 693 | 981 |
In their latest fiscal years, Editas Medicine, Inc. reported $40.52M in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: Editas Medicine, Inc. and GILEAD SCIENCES, INC., or browse the full rankings.